Literature DB >> 24249528

Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma.

Kazuhiro Migita1, Masayuki Sho, Keiji Shimada, Satoshi Yasuda, Ichiro Yamato, Tomoyoshi Takayama, Sohei Matsumoto, Kohei Wakatsuki, Kiyohiko Hotta, Tetsuya Tanaka, Masahiro Ito, Noboru Konishi, Yoshiyuki Nakajima.   

Abstract

BACKGROUND: Herpesvirus entry mediator (HVEM) is known to regulate immune response and to be expressed in several human malignancies. However, to the authors's knowledge, the precise role of HVEM in human cancer biology remains unknown. The objective of the current study was to clarify the clinical significance of HVEM in human esophageal squamous cell carcinoma as well as its in vivo functions.
METHODS: HVEM expression was evaluated in 103 patients with esophageal squamous cell carcinoma to explore its clinical relevance and prognostic value. The functions of HVEM in tumors were analyzed in vitro and in vivo using the small interfering RNA (siRNA) silencing technique.
RESULTS: HVEM expression was found to be significantly correlated with depth of tumor invasion and lymph node metastasis. Furthermore, it was found to be inversely correlated with tumor-infiltrating CD4(+) , CD8(+) , and CD45RO(+) lymphocytes. It is important to note that HVEM status was identified as an independent prognostic marker. HVEM gene silencing significantly inhibited cancer cell proliferation in vitro and cancer growth in vivo. This antitumor effect was associated with reduced cell proliferation activity. The effect was also correlated with the induction of CD8(+) cells and upregulation of local immune response.
CONCLUSIONS: HVEM plays a critical role in both tumor progression and the evasion of host antitumor immune responses, possibly through direct and indirect mechanisms. Therefore, HVEM may be a promising therapeutic target for human esophageal cancer.
© 2013 American Cancer Society.

Entities:  

Keywords:  esophageal squamous cell carcinoma; herpesvirus entry mediator (HVEM); immunotherapy; prognosis

Mesh:

Substances:

Year:  2013        PMID: 24249528     DOI: 10.1002/cncr.28491

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Comprehensive Urinomic Identification of Protein Alternatives to Creatinine Normalization for Diagnostic Assessment of Lupus Nephritis.

Authors:  Sanam Soomro; Samantha Stanley; Rongwei Lei; Ramesh Saxena; Michelle Petri; Chandra Mohan
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

2.  Mir-192 suppresses apoptosis and promotes proliferation in esophageal aquamous cell caicinoma by targeting Bim.

Authors:  Shujun Li; Feng Li; Ren Niu; Helin Zhang; Airong Cui; Wenting An; Xiaolu Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  MicroRNA-27a directly targets KRAS to inhibit cell proliferation in esophageal squamous cell carcinoma.

Authors:  Yuzhi Jiang; Yuting Duan; Haibin Zhou
Journal:  Oncol Lett       Date:  2014-11-11       Impact factor: 2.967

4.  Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis.

Authors:  Xiuwen Lan; Sen Li; Hongyu Gao; Abiyasi Nanding; Lina Quan; Chunyan Yang; Shaohua Ding; Yingwei Xue
Journal:  Onco Targets Ther       Date:  2017-02-16       Impact factor: 4.147

5.  HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.

Authors:  Nausicaa Malissen; Nicolas Macagno; Samuel Granjeaud; Clémence Granier; Vincent Moutardier; Caroline Gaudy-Marqueste; Nadia Habel; Marion Mandavit; Bernard Guillot; Christine Pasero; Eric Tartour; Robert Ballotti; Jean-Jacques Grob; Daniel Olive
Journal:  Oncoimmunology       Date:  2019-09-25       Impact factor: 8.110

6.  High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma.

Authors:  Bingqi Ma; Huijuan Meng; Ye Tian; Yingying Wang; Tianqiang Song; Ti Zhang; Qiang Wu; Yunlong Cui; Huikai Li; Wei Zhang; Qiang Li
Journal:  Oncol Lett       Date:  2020-11-25       Impact factor: 2.967

Review 7.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

8.  Association between BTLA polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population.

Authors:  Rui Cao; Weifeng Tang; Shuchen Chen
Journal:  J Clin Lab Anal       Date:  2020-02-15       Impact factor: 2.352

9.  Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells.

Authors:  Chia-Cheng Lin; Yu-Tang Chin; Ya-Jung Shih; Yi-Ru Chen; Yao-Yu Chung; Chi-Yu Lin; Chao-Nan Hsiung; Jacqueline Whang-Peng; Sheng-Yang Lee; Hung-Yun Lin; Paul J Davis; Kuan Wang
Journal:  J Dent Sci       Date:  2019-03-27       Impact factor: 2.080

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.